Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ Tcells in patients with acute myeloid leukemia.

Abstract

To characterize the distribution of Tcell immunoglobulin mucin-domain-containing-3 (Tim-3) within the exhausted Tcells in patients with newly diagnosed acute myeloid leukemia (AML) and AML in complete remission. Tim-3 expression and coexpression with PD-1, CD244, and CD57 in CD3+, CD4+, and CD8+Tcells were analyzed by multicolored fluorescent flow cytometry in peripheral blood from 28 newly diagnosed, untreated AML patient and 12 cases with AML in complete remission, 23 healthy individuals served as control. Increasing Tim-3+CD244+ and Tim-3+CD57+ in CD3+, CD4+, and CD8+ Tcells were found in AML and AML-CR groups in comparison with healthy controls. Similarly, increasing Tim-3 coexpression PD-1+ CD3+/CD4+/CD8+ Tcells were found in AML group. A high tendency of PD-1+Tim-3+CD3+/CD4+/CD8+ Tcells was detected in the AML-M4 subtype group followed by the M2 group, and a low tendency was found in the M3 group. Moreover, Tim-3+CD244+CD8+ Tcells were found to be significantly higher in the M4 than that in M3 group. Dynamic changes of Tim-3+ Tcells in AML patients who achieved CR after chemotherapy at different time points showed that Tim-3+ Tcell subsets were evidently decreased; however, they remained at a higher level in most AML-CR patients. We made a novel observation on distribution of Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ Tcells in patients with AML. Chemotherapy is incapable of resolving immunosuppression in some cases with AML in CR status.